KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Deffered Revenue: 2021-2024

Historic Non-Current Deffered Revenue for Travere Therapeutics (TVTX) over the last 2 years, with Mar 2024 value amounting to $888,000.

  • Travere Therapeutics' Non-Current Deffered Revenue fell 89.88% to $888,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $888,000, marking a year-over-year decrease of 89.88%. This contributed to the annual value of $1.8 million for FY2023, which is 83.21% down from last year.
  • Latest data reveals that Travere Therapeutics reported Non-Current Deffered Revenue of $888,000 as of Q1 2024, which was down 51.61% from $1.8 million recorded in Q4 2023.
  • Over the past 5 years, Travere Therapeutics' Non-Current Deffered Revenue peaked at $24.1 million during Q3 2021, and registered a low of $888,000 during Q1 2024.
  • In the last 3 years, Travere Therapeutics' Non-Current Deffered Revenue had a median value of $8.8 million in 2023 and averaged $9.2 million.
  • Data for Travere Therapeutics' Non-Current Deffered Revenue shows a maximum YoY crashed of 89.88% (in 2024) over the last 5 years.
  • Over the past 4 years, Travere Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $20.4 million in 2021, then crashed by 46.36% to $10.9 million in 2022, then slumped by 83.21% to $1.8 million in 2023, then tumbled by 89.88% to $888,000 in 2024.
  • Its Non-Current Deffered Revenue stands at $888,000 for Q1 2024, versus $1.8 million for Q4 2023 and $4.6 million for Q3 2023.